Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,890 | 5,680 | N/A | 1,760 | N/A |
| Marketable Securities | 0 | 0 | N/A | 9,950 | N/A |
| Other current assets | 150 | 120 | 70 | 20 | 0 |
| TOTAL | $7,040 | $5,800 | $70 | $11,730 | $N/A |
| Non-Current Assets | |||||
| PPE Net | 410 | 430 | 420 | 340 | N/A |
| Other Non-Current Assets | 10 | 10 | 10 | 60 | 0 |
| TOTAL | $420 | $440 | $430 | $400 | $N/A |
| Total Assets | $7,470 | $6,250 | $500 | $12,140 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 720 | 620 | 390 | 50 | 0 |
| Accrued Expenses | 740 | 1,070 | 970 | 1,030 | N/A |
| Other current liabilities | 3,510 | 3,720 | 0 | 200 | N/A |
| TOTAL | $5,020 | $5,470 | $1,370 | $1,320 | $N/A |
| Non-Current Liabilities | |||||
| TOTAL | $20 | $30 | $4 | $N/A | $N/A |
| Total Liabilities | $5,040 | $5,510 | $1,374 | $1,320 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1 | N/A | N/A | N/A | N/A |
| Common Shares | 2 | 2 | 1 | 1 | N/A |
| Retained earnings | -55,740 | -43,750 | N/A | -10,990 | N/A |
| Other shareholders' equity | 148 | 8 | 0 | -1 | 0 |
| TOTAL | $2,430 | $740 | $34,331 | $10,820 | $N/A |
| Total Liabilities And Equity | $7,470 | $6,250 | $35,705 | $12,140 | $0 |